Tuesday, 29 August 2017

Results of the "failed" rindopepimut ACTIV trial published

Rindopepimut with temozolomide for patients with newlydiagnosed, EGFRvIII-expressing glioblastoma (ACT IV):a randomised, double-blind, international phase 3 trial
Posted by at
Labels: ,

1 comment:

Subscribe to: Post Comments (Atom)